Michael Eisenberg, MD, a urologist and professor specializing in male sexual function and fertility at Stanford University
The DREAM-SEQ trial is a landmark study that demonstrated superiority of frontline ICI combination versus combination BRAFMEK inhibition as frontline therapy for patients with BRAF V600E/K -mutant, advanced melanoma
Erabi H, Okada G, Shibasaki C, Setoyama D, Kang D, Takamura M, et al
or eye problems caused by diabetes (retinopathy)
Another interesting compound, quercetin, has been shown to inhibit the activity of CD38 by binding to its active site, which results in increased intracellular NAD + 143
Seven additional Phase 3 trials from the TRIUMPH program are expected to report results throughout 2026, including trials in type 2 diabetes, obstructive sleep apnea, and general obesity without specific comorbidities